Lung neoplasm

Summary

Lung neoplasm (MONDO:0021117) is a cancer (an umbrella term covering 10 Mondo subtypes) and 498 clinical trials. Top therapeutic interventions include pemetrexed, indocyanine green acid form, and osimertinib. A subtype of lung disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Umbrella term: 10 Mondo subtypes
• Clinical trials: 498

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	lung neoplasm
Mondo ID	MONDO:0021117
MeSH	D008175
NCIT	C3200
UMLS	C0024121
MedGen	7400
Anatomy (UBERON)	UBERON:0002048
Is cancer (heuristic)	yes

Also known as: lung · lung neoplasm · lung neoplasm (disease) · lung neoplasms · lung tumor · lung tumour · neoplasm of lung · neoplasm of the lung · neoplasm, lung · neoplasm, pulmonary · neoplasms, lung · neoplasms, pulmonary · tumor of lung · tumor of the lung · tumour of lung · tumour of the lung

Data availability: 1 cell line · 8 intOGen driver records.

Disease family

This is a subtype of lung disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › lower respiratory tract disorder › lung disorder › lung neoplasm

Related subtypes (32): aspiration pneumonia, lung abscess, pneumonic plague, pulmonary alveolar proteinosis, pulmonary systemic sclerosis, obstructive lung disease, bronchiolitis, pulmonary immaturity, rheumatoid arthritis-associated interstitial lung disease, pulmonary embolism and infarction, acute chest syndrome, fungal lung infectious disease, middle lobe syndrome, pulmonary coin lesion, pulmonary plasma cell granuloma, silo filler disease, pulmonary alveolar microlithiasis, pulmonary venoocclusive disease, acute lung injury, interstitial lung disease, hantavirus pulmonary syndrome, pulmonary non-tuberculous mycobacterial infection, respiratory failure, occupational lung disease, Wilson-Mikity syndrome, neonatal aspiration syndrome, pneumonitis, vanishing lung syndrome, restrictive pulmonary disease, shrinking lung syndrome, dystrophic pulmonary ossification, pulmonary artery disease

Subtypes (10): lung benign neoplasm, lung hilum neoplasm, lung neuroendocrine neoplasm, lung cancer, Langerhans cell histiocytosis specific to adulthood, lung PEComa, fibroma of lung, hamartoma of lung, pulmonary sulcus neoplasm, lung germ cell tumor

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

3 approved, 67 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Atezolizumab	Approved (phase 4)
Cemiplimab	Approved (phase 4)
Etoposide	Approved (phase 4)
Amifostine	Phase 3 (in late-stage trials)
Amrubicin	Phase 3 (in late-stage trials)
Aumolertinib	Phase 3 (in late-stage trials)
Bcg Vaccine	Phase 3 (in late-stage trials)
Bevacizumab	Phase 3 (in late-stage trials)
Bintrafusp Alfa	Phase 3 (in late-stage trials)
Brigatinib	Phase 3 (in late-stage trials)
Bupivacaine	Phase 3 (in late-stage trials)
Canakinumab	Phase 3 (in late-stage trials)
Carboplatin	Phase 3 (in late-stage trials)
Catequentinib	Phase 3 (in late-stage trials)
Celecoxib	Phase 3 (in late-stage trials)
Cetuximab	Phase 3 (in late-stage trials)
Cisplatin	Phase 3 (in late-stage trials)
Crizotinib	Phase 3 (in late-stage trials)
Dacomitinib Anhydrous	Phase 3 (in late-stage trials)
Dalteparin Sodium	Phase 3 (in late-stage trials)
Denosumab	Phase 3 (in late-stage trials)
Durvalumab	Phase 3 (in late-stage trials)
Efaproxiral	Phase 3 (in late-stage trials)
Endostatin, N-Terminal-Mggshhhhh	Phase 3 (in late-stage trials)
Epacadostat	Phase 3 (in late-stage trials)
Epinephrine	Phase 3 (in late-stage trials)
Epoetin Alfa	Phase 3 (in late-stage trials)
Erlotinib	Phase 3 (in late-stage trials)
Etoposide Phosphate	Phase 3 (in late-stage trials)
Filgrastim	Phase 3 (in late-stage trials)
Gefitinib	Phase 3 (in late-stage trials)
Gemcitabine	Phase 3 (in late-stage trials)
Icotinib	Phase 3 (in late-stage trials)
Ifosfamide	Phase 3 (in late-stage trials)
Infliximab	Phase 3 (in late-stage trials)
Ipilimumab	Phase 3 (in late-stage trials)
Irinotecan	Phase 3 (in late-stage trials)
Isotretinoin	Phase 3 (in late-stage trials)
Linrodostat	Phase 3 (in late-stage trials)
Marimastat	Phase 3 (in late-stage trials)
Mitomycin	Phase 3 (in late-stage trials)
Mitumomab	Phase 3 (in late-stage trials)
Nadroparin Calcium	Phase 3 (in late-stage trials)
Nicotine	Phase 3 (in late-stage trials)
Nivolumab	Phase 3 (in late-stage trials)
Olaparib	Phase 3 (in late-stage trials)
Osimertinib	Phase 3 (in late-stage trials)
Paclitaxel	Phase 3 (in late-stage trials)
Paclitaxel Poliglumex	Phase 3 (in late-stage trials)
Patritumab	Phase 3 (in late-stage trials)
Pegfilgrastim	Phase 3 (in late-stage trials)
Pembrolizumab	Phase 3 (in late-stage trials)
Pemetrexed	Phase 3 (in late-stage trials)
Penpulimab	Phase 3 (in late-stage trials)
Platinum	Phase 3 (in late-stage trials)
Prinomastat	Phase 3 (in late-stage trials)
Sintilimab	Phase 3 (in late-stage trials)
Tacedinaline	Phase 3 (in late-stage trials)
Talabostat	Phase 3 (in late-stage trials)
Thalidomide	Phase 3 (in late-stage trials)
Tirapazamine	Phase 3 (in late-stage trials)
Topotecan	Phase 3 (in late-stage trials)
Uridine Triphosphate	Phase 3 (in late-stage trials)
Vandetanib	Phase 3 (in late-stage trials)
Varenicline	Phase 3 (in late-stage trials)
Vibostolimab	Phase 3 (in late-stage trials)
Vinblastine	Phase 3 (in late-stage trials)
Vindesine	Phase 3 (in late-stage trials)
Vinorelbine	Phase 3 (in late-stage trials)
Vorinostat	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): ANTINEOPLASTON A10, Abemaciclib, Afatinib, Aldesleukin, Alectinib, Arsenic Trioxide, Ascorbic Acid, Axitinib, Becatecarin, Belagenpumatucel-L, Bexarotene, Bortezomib, Budesonide, Cabozantinib, Cadonilimab, Camrelizumab, Capecitabine, Capmatinib, Certolizumab, Charcoal, Activated, Cyanocobalamin, Dabrafenib, Dasatinib Anhydrous, Datopotamab Deruxtecan, Decitabine, Defactinib, Dexamethasone, Doxorubicin, Endostatin, Ensartinib, Envafolimab, Enzastaurin, Epigalocatechin Gallate, Everolimus, Evolocumab, Exisulind, Fenretinide, Firmonertinib, Folic Acid, Fruquintinib, Fulvestrant, Glufosfamide, Hydroxychloroquine, Iloprost, Imatinib, Incomplete Freund’S Adjuvant, Interferon Alfa, Irofulven, Itraconazole, Ixabepilone, Karenitecin, Ketamine, Keyhole Limpet Hemocyanin, Laromustine, Lazertinib, Lomustine, Lorlatinib, Metformin, Minocycline, Motexafin Gadolinium, Muparfostat, Nimotuzumab, Nintedanib, Nitroglycerin, OMEGA-3 FATTY ACIDS, Oblimersen Sodium, Oxaliplatin, Panitumumab, Pazopanib, Picoplatin, Pioglitazone, Pirfenidone, Porfimer Sodium, Poziotinib, Pralatrexate, Prednisone, Propofol, QS-21, Ramucirumab, Regramostim, Reminertant, Retlirafusp Alfa, Risedronic Acid, Rituximab, Rivoceranib, Rocuronium, Rubitecan, Sacituzumab Govitecan, Sargramostim, Satraplatin, Savolitinib, Selenomethionine, Selumetinib, Sevoflurane, Simvastatin, Sodium Chloride, Sodium Dichloroacetate, Sorafenib, Sotorasib, Spartalizumab, Sulforaphane, Sunitinib, Tafolecimab, Tecemotide, Temozolomide, Tipifarnib, Tislelizumab, Toripalimab, Trabedersen, Trametinib, Trastuzumab, Tremelimumab, Tretinoin, Triapine, Trilaciclib, Vadimezan, Vinflunine, Vitamin E, Volociximab, Zibotentan, Zileuton.

Clinical trials & evidence

Clinical trials

Clinical trials: 498.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	314
PHASE2	87
PHASE1	27
PHASE1/PHASE2	26
PHASE3	23
PHASE4	11
PHASE2/PHASE3	5
EARLY_PHASE1	5

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00338481	PHASE4	COMPLETED	Red Morphine Drops for Symptomatic Treatment of Dyspnoea in Lung Cancer
NCT00925444	PHASE4	COMPLETED	Staple-line Reinforcement for Prevention of Pulmonary Air Leakage
NCT01064050	PHASE4	TERMINATED	Role of a Silicone Prosthesis to Prevent Airway Obstruction Recurrence in Lung Cancers
NCT01658280	PHASE4	COMPLETED	Conventional Versus Ultrasound-guided Transbronchial Needle Aspiration for the Diagnosis of Hilar/Mediastinal Lymphadenopathies
NCT01783236	PHASE4	COMPLETED	Analgesic Efficacy of Intravenous Acetaminophen After Video-assisted Thoracic Surgery
NCT02151149	PHASE4	COMPLETED	Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly
NCT02359175	PHASE4	COMPLETED	Supplementary Epidural Analgesia in Video-Assisted Thoracic Surgery (VATS) - The SEAVATS Study
NCT02744664	PHASE4	COMPLETED	Cryotherapy Combine Icotinib for Advanced NSCLC Treatment
NCT05121233	PHASE4	UNKNOWN	Local Anesthesia Versus Combined Local Anesthesia With Single Dose Analgesia on Pain Control During Thoracic Ultrasound Guided Procedures
NCT05834569	PHASE4	TERMINATED	Impact of Maxigesic on Delirium After Minimally Invasive Lung Surgery in Elderly Patients
NCT05850702	PHASE4	UNKNOWN	Attenuation of the Hemodynamic Response to Double-lumen Endotracheal Intubation With Nebulized Lidocaine
NCT04380636	PHASE3	ACTIVE_NOT_RECRUITING	Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
NCT05786716	PHASE2/PHASE3	RECRUITING	DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations
NCT07099898	PHASE3	RECRUITING	A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)
NCT00123760	PHASE2/PHASE3	COMPLETED	Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Cancer or Suspected Cancer
NCT00174629	PHASE3	COMPLETED	GILT Docetaxel - Non-Small Cell Lung Cancer
NCT00243685	PHASE2/PHASE3	COMPLETED	Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
NCT00290017	PHASE3	TERMINATED	Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy
NCT00657423	PHASE3	UNKNOWN	Impact of Endostar Combined With Chemotherapy on the Angiogenesis of Advanced Non-small Cell Lung Cancer (NSCLC)
NCT00676507	PHASE3	COMPLETED	Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy
NCT01038661	PHASE3	COMPLETED	Tax First-line Chemotherapy With Different Doses and Then Maintenance Therapy
NCT01631565	PHASE3	COMPLETED	Early Incorporation of Patient and Family to Attention and Care Program in Oncology Versus Standard of Care
NCT01687647	PHASE3	TERMINATED	Sputum Cytometry Analysis in Lung Cancer Screening After Professional Asbestos Exposure
NCT02393664	PHASE2/PHASE3	UNKNOWN	Effects of Nonintubated Versus Intubated General Anesthesia on Recovery After Thoracoscopic Lung Resection
NCT02518802	PHASE3	UNKNOWN	Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung Adenocarcinoma
NCT02688036	PHASE3	COMPLETED	Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LD-SCLC
NCT02790190	PHASE3	UNKNOWN	Individualized Adaptive Radiotherapy Based on PET/CT and IMRT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT02845479	PHASE3	COMPLETED	The Thoracic Peri-Operative Integrative Surgical Care Evaluation (POISE) Trial- Stage I
NCT02906280	PHASE3	UNKNOWN	RCT Comparing 19Ga vs 22Ga EBUS-TBNA Needles in Carcinoma.
NCT03090880	PHASE3	TERMINATED	Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE)
NCT03134872	PHASE3	COMPLETED	A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC
NCT03331588	PHASE3	COMPLETED	Comparison of Post-operative Pain and Quality of Life Between Subxiphoid and Intercostal VATS for Lung Cancer
NCT03380468	PHASE2/PHASE3	UNKNOWN	Adjuvant Chemotherapy for High Risk Stage I Lung Adenocarcinoma
NCT03402048	PHASE3	UNKNOWN	The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial
NCT03607539	PHASE3	COMPLETED	Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC
NCT04222972	PHASE3	TERMINATED	A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT04241315	PHASE3	COMPLETED	ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting
NCT04490421	PHASE3	UNKNOWN	Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer.
NCT04738487	PHASE3	COMPLETED	Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)
NCT01770418	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PEMETREXED	4	7
INDOCYANINE GREEN ACID FORM	4	4
OSIMERTINIB	4	4
DOCETAXEL ANHYDROUS	4	3
AFATINIB	4	2
OLAPARIB	4	2
PAFOLACIANINE	4	2
PRALSETINIB	4	2
ALECTINIB	4	1
AXITINIB	4	1
CARBOPLATIN	4	1
COSIBELIMAB	4	1
DACOMITINIB	4	1
DALTEPARIN SODIUM	4	1
DARBEPOETIN ALFA	4	1
DICLOFENAC	4	1
DURVALUMAB	4	1
FONDAPARINUX	4	1
FONDAPARINUX SODIUM	4	1
GEFITINIB	4	1
GEMCITABINE	4	1
LOMUSTINE	4	1
MOBOCERTINIB	4	1
MORPHINE	4	1
NADROPARIN CALCIUM	4	1
NERATINIB	4	1
NIRAPARIB	4	1
PEGVISOMANT	4	1
PERTUZUMAB	4	1
PLICAMYCIN	4	1